Trilaciclib, a CDK 4/6 Inhibitor, in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer (mCRC):
Conditions: Colorectal Cancer Metastatic; Myelosuppression Adult; Chemotherapeutic Toxicity Interventions: Drug: Trilaciclib; Drug: Placebo Sponsor: G1 Therapeutics, Inc. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials